Merck KGaA nabs another baton in protein degradation race with $554M Proxygen deal
Merck KGaA nabs another baton in protein degradation race with [...]
Oncology trial starts hit record levels as COVID disruptions ease: report
Oncology trial starts hit record levels as COVID disruptions ease: [...]
Samantha Truex did a rare thing last time she was CEO: admit defeat. She’s back with a new biotech and $200M
Samantha Truex did a rare thing last time she was [...]
Amgen’s heart drug reduces cardiovascular disease risk factor in phase 2 trial
Amgen’s heart drug reduces cardiovascular disease risk factor in phase [...]
BioMarin’s hemophilia A gene therapy further delayed amid new FDA questions
BioMarin’s hemophilia A gene therapy further delayed amid new FDA [...]
Sanofi’s Hemlibra rival gets step closer to approval with FDA breakthrough tag
Sanofi’s Hemlibra rival gets step closer to approval with FDA [...]
After Axsome’s migraine med rejection, phase 3 data keeps hope alive for depression drug
After Axsome’s migraine med rejection, phase 3 data keeps hope [...]
After oncology wind-down, TG’s pivot to MS faces setback as FDA pushes approval decision
After oncology wind-down, TG’s pivot to MS faces setback as [...]
Bouncing back from late-phase fail, Minoryx pockets €51M to guide rare disease drug to market
Bouncing back from late-phase fail, Minoryx pockets €51M to guide [...]
ASCO: Mirati cedes to Amgen’s Lumakras on durability in tight KRAS battle
ASCO: Mirati cedes to Amgen’s Lumakras on durability in tight [...]